Held May 18–21 in the Beskydy Mountains (Czech Republic), HPCSE 2026 brought together leading experts in high-performance computing, applied mathematics, AI, and quantum computing under the banner of IT4Innovations National Supercomputing Center. Paulo Silva from IT4Innovations, partner of AVITHRAPID, attended the conference and presented a poster “Enabling HPC-Accelerated Virtual Screening for Drug Discovery through the LEXIS Platform” at the poster session, promoting the activities of the project. For AVITHRAPID, the EU Horizon Europe project building a pre-clinical drug discovery pipeline using sophisticated computational methods to rapidly respond to novel viral infections, a venue like

The International Society for Antiviral Research (ISAR) hosted the 39th International Conference on Antiviral Research (ICAR), bringing together leading scientists, researchers, and industry professionals to discuss the latest advancements and breakthroughs in antiviral research, from Monday, April 27th to Friday, May 1st in Prague, Czech Republic. At ICAR, scientists working throughout the world in all areas of discovery, applied, translational, or clinical research and development met in a collaborative and collegial atmosphere to review and analyze most recent developments in all areas related to antiviral drug discovery and development.  We are proud to see

At SCA/HPCAsia 2026 in Japan, AVITHRAPID was represented through a poster showcasing how high-performance computing infrastructures can enable scalable and user-oriented virtual screening workflows for drug discovery.The poster, presented by Paulo Silva from IT4Innovations National Supercomputing Center, illustrates an integrated approach combining: federated access to European HPC resources; workflow orchestration through the LEXIS Platform and an ergonomic interface simplifying large-scale virtual screening execution and monitoring. This work, developed and presented within the AVITHRAPID framework, highlights how advanced digital infrastructures can support computational readiness for antiviral research in a pandemic preparedness context.We also acknowledge the

The AVITHRAPID consortium had a great opportunity to present its ambitious objectives and results during the International Conference for High Performance computing, networking, storage, and analysis in St. Louis, US, on November 17th-21st.  SC is an unparalleled mix of thousands of scientists, engineers, researchers, educators, programmers, and developers who intermingle to learn, share, and grow.  A worldwide event to meet and interact with industry, research organizations, universities, and startups joining together from across the globe. 16,500 attendees and 559 exhibitors met during the 4-days event.   IT4Innovations at VSB – Technical University of Ostrava, partner

The 25th AREVIR Meeting featured a special joint session dedicated to AVITHRAPID projectThis session also included presentations by the lead scientists from different projects, covering preliminary activities, current findings, and future steps to address evolving challenges. EuResist, member of AVITHRAPID consortium, presented the project to an audience of more than 100 people (infectious diseases specialists, virologists, AI researchers), as part of the international meeting that has been held in Cologne for over 15 years. Francesca Incardona’s talk highlighted AVITHRAPID’s rapid-response approach to future pandemics, leveraging high-performance computing and real-world collaboration across disciplines. The session also

On 16 and 17 of June, members of our consortium from across Europe came together for a dedicated two-day general meeting focused on shaping the future of antiviral development. This exclusive meeting was designed to foster strategic dialogue, operational alignment, and scientific exchange among project partners, creating space for deeper collaboration and forward-looking vision. Throughout the event, we monitored and evaluate the current status of the project, examining achievements to date, unresolved challenges, and next steps.  This meeting provided also the opportunity to connect more closely with fellow consortium members, strengthen the coherence of

The partners of AVITHRAPID strive to disseminate project activities during key scientific events, both at local and international level. High-profile conferences are pivotal opportunities to meet academia and industries and confront with state-of-the-art research in AVITHRAPID-related topics. This INF-ACT conference, held in Naples on April 3rd-5th, offered a broad and important opportunity for networking to discuss the latest research developments in the field of emerging infectious diseases with a multidisciplinary and One Health approach. The program included a day of round tables with stakeholders from important public and private sectors on the role and

Francesca Incardona of EuResist network, member of Avithrapid consortium, was in Bologna to explore international collaborations at a 2 days workshop for infectious diseases specialists and virologists: the ARCA (Antiretroviral Resistance Cohort Analysis) Factory event (Bologna 30 Sept-1 October).ARCA Factory (https://www.informapro.it/arca.html) is one of the educational events organised by ARCA (http://www.hivARCA.net) a large HIV Italian cohort focused on resistance, led by Maurizio Zazzi at UniSiena and with the technical support of I-PRO (EuResist). ARCA is a public database for the studying of resistance to anti-HIV drugs (antiretroviral drugs). It is fed by data coming from